profile icon
Dr

Na Li

Honorary
The Sir Peter Maccallum Department Of Oncology
science & technology
cisplatin
cyclophosphamide
predictors
dose reductions
ovarian cancer
intensity
patient outcomes
chemotherapy
Na Li's Profile Picture
Dr

Na Li

 
Division
Medicine, Dentistry And Health Sciences
Na Li's Profile Picture
Dr

Na Li

 

Find out more about Na Li's experience

Na Li's highlights

Projects

Displaying the most recent project by Na Li.

Project icon

Validation Of Novel Breast Cancer Predisposition Genes Identified In The Halo Study; A Large-Scale Familial Breast Cancer Case-Control Dataset

2020 - 2020
Active

1

Projects

Project Types

1

Research Grant

Scholarly Works

Displaying the 2 most recent scholarly works by Na Li.

Scholarly works icon

Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study

T Sivakumaran, L Mileshkin, P Grant, L Na, A DeFazio, M Friedlander, A Obermair, PM Webb, G Au-Yeung

Journal article  |  2020  |  Gynecologic Oncology

OBJECTIVES: To determine the impact of chemotherapy dose reductions and dose delays on progression-free survival (PFS) in women wi..

Scholarly works icon

Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes

Deepak N Subramanian, Magnus Zethoven, Simone McInerny, James A Morgan, Simone M Rowley, Jue Er Amanda Lee, Na Li, Kylie L Gorringe, Paul A James, Ian G Campbell

Journal article  |  2020  |  Nature Communications

High-grade serous ovarian carcinoma (HGSOC) has a significant hereditary component, approximately half of which cannot be explaine..

2

Scholarly Works

Keyword Analysis

Oncology and Carcinogenesis
Clinical Health (organs, Diseases and Abnormal Conditions)
Expanding Knowledge

Credentials

Positions

Honorary

The Sir Peter Maccallum Department Of Oncology